The Antitubucular Activities of 2-[(E-2-Substituted-Ethenyl)] and its Characterization and Pharmacological Evaluation Devices Of 1,3-Benzoxazoles

Abstract

Mycobacterium tuberculosis remains one of the world’s most significant infectious disease threats, complicated by slow growth, intrinsic resistance mechanisms, and the emergence of multidrug-resistant strains. In the search for new therapeutic agents, heterocyclic scaffolds such as benzoxazoles have shown promise due to their diverse biological activities. This study investigates the synthesis, characterization, and antitubercular potential of 2-[(E)-2-Phenylethenyl]-1,3-benzoxazole. The compound was structurally confirmed by NMR, IR, MS, and HPLC analysis and evaluated for in-vitro inhibitory activity against Mycobacterium tuberculosis H37Rv, Mycobacterium avium, and Mycobacterium kansasii using the resazurin microtiter assay. Results revealed minimum inhibitory concentrations (MICs) of 125 µmol/L, 62.5 µmol/L, and 125 µmol/L against the respective strains, demonstrating moderate antitubercular activity. These findings highlight the potential of benzoxazole derivatives as lead molecules for developing novel antimycobacterial agents. Further structural modifications and pharmacological evaluations are warranted to optimize efficacy and reduce toxicity.